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PDC). The outcome was adherence to AH drugs in the 6-month post-index period.
Logistic regression analysis was conducted to explore the impact of CVD hospital-
izations on changes in adherence to AH drugs. RESULTS: There were 1332 patients
with AH drugs. Patients with a CVD hospitalizationwere 2.9 times (95% Confidence
Interval: 2.1-3.9) more likely to be adherent in the 6-month post-index period com-
pared to control patients. Among patients with a CVD hospitalization, the propor-
tion of patients who were non-adherent to AH drugs in the 6-month post-index
period was 30.6%. CONCLUSIONS: Patient adherence to AH drugs improved after a
CVD hospitalization, but there was still a substantial proportion of patients who
were non-adherent after that hospitalization. Counseling patients on medication
adherence during their hospitalizationmay be an effective way for improving their
adherence following discharge.
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OBJECTIVES: To estimate patient adherence with once-a-day (QD) vs. twice-a-day
(BID) chronic medications following hospital discharge for ACS. METHODS: A ret-
rospective cohort study of patients discharged between 1/1/2007 and 4/30/2009
with an ACS diagnosis was performed using a large hospital and pharmacy claims
dataset. Two chronic medications dispensed for QD and BID utilization, carvedilol
andmetformin, were analyzed for adherencemeasures [persistency, days on ther-
apy, compliance (medication possession ratio, MPR), total # of dispensed prescrip-
tions, gap (days) between refills] over a 12 month post-index period. Included pa-
tients had first dispensed prescription of carvedilol or metformin within 60 days of
discharge (index prescription) and had Rx activity for any drug  12 months post-
index. Persistence was defined as percentage of patients without a therapy lapse
of  30 days from last dispensed day’s supply. RESULTS: Persistency with carve-
dilol QD vs. BID (N168 vs. 2086) at 6 months was 44.0% vs 43.7% and at 12 months
was 24.4% vs. 25.5%. Persistency with metformin QD vs. BID (N136 vs. 614) at 6
months was 50.7% vs 53.7% and at 12 months was 28.7 vs. 35.0%. The average days
on therapy for carvedilol QD vs. BID at 6 months was 120.5 vs. 121.9 and at 12
months was 196.7 vs. 203.0. Average days on therapy for metformin QD vs. BID at 6
monthswas 123.6 vs. 136.2 and at 12monthswas 206.1 vs. 237.7. Compliance (MPR)
with QD vs. BID carvedilol at 12months was 84.2% vs 80.7% and for metformin was
77.6% vs 81.6%. Additional adherence metrics were consistent for QD vs. BID
dosing. CONCLUSIONS: In ACS patients, no clinically meaningful differences on
adherence measures were observed between QD versus BID dosing formulations
over a 12 month follow-up period. Results indicate potential opportunities to im-
prove persistency with chronic therapies in ACS patients.
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OBJECTIVES: Justification for the Use of Statins in Prevention: an Intervention Trial
Evaluating Rosuvastatin (JUPITER) demonstrated a statin benefit for primary pre-
vention. However, real-world patientsmay not exhibit medication persistence and
adherence seen in the trial. We described persistence and adherence of first-time
statin users. METHODS: A 10% random sample of the IMS LifeLink Health Plan
Claims Database was used to obtain prescription claims records for adult (18
years) first-time statin users with continuous health plan eligibility 12 months
prior and 32 months after the index statin prescription between July 1, 1997 and
December 31, 2008. Persistence and adherence were measured during the 24
months after statin initiation. Patients were persistent if gaps in statin use did not
exceed 180 consecutive days. Adherence was measured as the medication posses-
sion ratio (MPR) during the period of persistence. Persistence groups were catego-
rized as ‘short’ (9 months), ‘intermediate’ (9-16 months) and ‘long’ (17months)
and compared using ANOVA. RESULTS: Among 26,530 new statin users, the mean
length of persistence was 17months. The proportions in each persistence category
were: 21% ‘short’, 12% ‘intermediate’ and 68% ‘long’. 32% were persistent for 24
months or more, as compared to 75% of JUPITER patients taking medication after
the median 1.9 year study period. Mean MPR of the ‘intermediate’ and ‘short’ per-
sistence categories were similar (0.70 vs. 0.69, P.15), but lower than the overall
mean MPR of 0.80. Mean MPR was greatest in the ‘long’ persistence category (0.85,
P.0001) and was higher than the overall mean MPR. CONCLUSIONS: Persistence
and adherence measure two different but critical concepts: the length of time
patients use statins and their adherence to the statin regimen during that period,
which we found to vary. Extrapolating the primary prevention benefits of statins
must account for both measures, as they differ from clinical trials to practice.
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OBJECTIVES: Several studies have demonstrated that higher patient out-of pocket
cost may result in lower medication adherence. The purpose of this study was to
measure Medication Possession Ratio (MPR) among patients newly-prescribed a
brand or generic statin medication in a managed Medicaid plan and a commercial
health plan. METHODS: We conducted a retrospective analysis using pharmacy
claims data to identify patients who were new to statin treatment (no pharmacy
claim for a lipid-lowering medication in the previous 12 months). Patients were
categorized based on their index medication. We used a Robust linear regression
model to determine predictors of adherence. RESULTS: A total of 738 commercial
patients and 2175 Medicaid patients were included. Sixty percent of Medicaid pa-
tients and 49% of commercial patients initiated therapywith a genericmedication.
Average patient out-of-pocket cost for commercial plan patients was $9/month for
generic and $15/month for brand. Medicaid patients had no copayment for generic
or brand medications. In the commercial plan, there was no significant difference
in MPR between patients who initiated therapy with generic or brand statins (MPR
0.75 vs. 0.73, respectively). In the Medicaid plan, MPR was significantly higher
among patients who started on generic medications (0.69 vs. 0.63). In robust linear
regression, MPR was significantly related to age, number of comorbidities and ge-
neric use. After we adjusted MPR for age and comorbidities, MPR remained signif-
icantly higher in the Medicaid generic group. CONCLUSIONS: Medicaid patients
prescribed a generic statin as initial therapy were more adherent than those pre-
scribed a brand, despite having no copayment for generic or brand medications.
This differencewas not present among commercial plan patientswho had a higher
cost share for brandmedications. This suggests that additional research is needed
to identify non-financial barriers to adherence.
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OBJECTIVES: To examine statin adherence and persistence among patients receiv-
ing treatment for secondary prevention of coronary heart disease (CHD) at US
Military Treatment Facilities (MTF) within the Department of Defense (DoD).
METHODS: Retrospective cohort study utilizing the DoD Military Health System
database to examine 21,053 TRICARE beneficiaries between 18-75 years of age,
receiving medical services for a primary CHD event at an MTF between January 1,
2004 and December 31, 2008. Drug adherence was measured using the Medication
Possession Ratio (MPR) at 6, 12 and 18 months. Persistence was measured as dura-
tion of statin-therapy based on35-day refill gap. Covariates included age, gender,
comorbidities, drug-switching and dosage titration. Logistic regression was con-
ducted to assess predictors of adherence [95% Confidence-Intervals]. RESULTS:
The CHD cohort (N21,053) was 74% male with a mean age of 57.4(SD8.8) years.
Overall mean MPR was 89%(SD22) at month six (M6), 84%(SD25) at 12-months
(M12), and 81%(SD26.4) after 18-months (M18). Approximately 80% of patients
were adherent (MPR80%)with statin-therapy atM6which declined to 71% atM12,
and 69% at the end of M18 (p.001). Older male patients with hyperlipidemia were
more adherent. Adjusting for covariates, patients were more likely to be adherent
at M6, M12, and M18 that switched statins (OR1.87[1.65-2.13],1.3[1.24-1.46], and
1.07[1.00-1.15]) or had at least one titration adjustment (OR2.99[2.62-3.40],1.86
[1.72-2.01], and 1.54[1.44-1.65]) compared to patients with no therapeutic adjust-
ments. Overall mean persistence to statins was 322 days. Patients experiencing
35-day refill gap increased from 34% to 53% to 63% at 6, 12, and 18-months
respectively. CONCLUSIONS: This study showed statin adherencewas high among
DoD patients receiving medical care at MTFs for secondary prevention of CHD
during the first 6-months. Adherence and persistence, however, declined bymonth
12. Improved patient adherence was associated with closer monitoring of pre-
scribed therapy, as seen among patients who were titrated or switched statins.
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OBJECTIVES: A recent study by our team indicated that approximately 13% of
prescribed venous thromboembolism (VTE) prophylactic doses are not adminis-
tered. The goal of this study was to determine documented reasons and describe
the distribution patterns for non-administered VTE prophylaxis doses.METHODS:
We conducted a retrospective review of electronic medication administration re-
cords using our computerized physician order entry system. The study included
hospitalized patients aged 18 years or older who were ordered pharmacologic VTE
prophylaxis from December 1, 2007 through June 30, 2008. RESULTS: A total of
108,533 VTE prophylaxis doses were ordered for 8,607 patients. 12.8% of ordered
doses were not administered. Non-administration rates varied by patient floor
from 4.8% to 33.9%. Approximately 53% of doses that were not administered (6.8%
of all doses) were documented as patient refusal – the most common documented
reason for non-administration of VTE prophylaxis by a widemargin. Patient refus-
als varied greatly by nursing unit, ranging from less than 1% to 19% of ordered
doses. Patient refusals were highly concentrated on certain nursing units; 5 nurs-
ing units accounted for two-thirds of all refused doses. A small number of patients
accounted for the vastmajority of refused doses; 11% of patients who refusedmore
than 1 dose accounted for nearly 87% of all refused doses. CONCLUSIONS: Patient
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